DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2003/0078266A1 Kararli Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2003/0078266A1 Kararli Et Al US 2003OO78266A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0078266A1 Kararli et al. (43) Pub. Date: Apr. 24, 2003 (54) RECONSTITUTABLE PARENTERAL Publication Classification COMPOSITION 51)1) Int. Cl.'C.7 ....................... A61K 31/5050; A61K 31/415;5 A61K 31/353; A61K 31/12 (76) Inventors: Tugrul T. Kararli, Skokie, IL (US); (52) U.S. Cl. ......................... 514/247; 514/406; 514/456; Sandeep Nema, Grayslake, IL (US); 514/690 Aziz Karim, Skokie, IL (US) (57) ABSTRACT Correspondence Address: Pharmacia Corporation Corporate Patent Department A pharmaceutical composition comprises, in powder form, (a) at least one water-Soluble therapeutic agent Selected from 800 N. Lindbergh Boulevard - 04B Selective COX-2 inhibitory drugs and prodrugs and Salts St. Louis, MO 63167 (US) thereof, for example parecoxib Sodium, in a therapeutically effective total amount constituting about 30% to about 90% (21) Appl. No.: 10/113,281 by weight, (b) a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and optionally (22) Filed: Apr. 1, 2002 (c) other parenterally acceptable excipient ingredients in a total amount not greater than about 10% by weight, of the Related U.S. Application Data composition. The composition is reconstitutable in a parenterally acceptable Solvent liquid to form an injectable (60) Provisional application No. 60/281,058, filed on Apr. Solution. Alyophilization process is provided for preparation 3, 2001. of Such a composition. Patent Application Publication Apr. 24, 2003 US 2003/0078266A1 -0-parecoxib IV 233 OOO - - - O - - ValdeCOxib oral 200 - 150 - 100 - 5 O O O 4 8 12 16 20 24 hours after administration Fig. 1 US 2003/0078266 A1 Apr. 24, 2003 RECONSTITUTABLE PARENTERAL use are effective analgesics but have been associated with COMPOSITION side effects typical of Such non-selective NSAIDs. These 0001. This application claims priority of U.S. provisional Side effects have included upper gastrointestinal tract ulcer application Serial No. 60/281,058, filed on Apr. 3, 2001. ation and bleeding, particularly in elderly Subjects, reduced renal function, potentially leading to fluid retention and FIELD OF THE INVENTION exacerbation of hypertension; and inhibition of platelet function, potentially predisposing the Subject to increased 0002 The present invention relates to water-soluble Selective cyclooxygenase-2 (COX-2) inhibitory drugs and bleeding, for example during Surgery. Such side effects have Salts and prodrugs thereof and in particular to parecoxib, for Seriously limited the use of parenteral formulations of non example in the form of its Sodium salt (parecoxib Sodium). Selective NSAIDs. Parecoxib is a water-soluble prodrug of the selective COX-2 inhibitory drug Valdecoxib. More particularly, the invention 0006. It would therefore represent a further significant relates to parenterally deliverable, for example injectable, advance in the art if a parenterally deliverable formulation of formulations of water-soluble selective COX-2 inhibitory a selective COX-2 inhibitory drug could be provided. drugs and Salts and prodrugs thereof. Even more particu larly, the invention relates to Such formulations that are 0007. It is known to prepare parenteral formulations by a prepared as powders for reconstitution in an aqueous carrier process of lyophilization (freeze-drying) of an aqueous prior to parenteral administration. The invention also relates Solution of the therapeutic agent. See for example Reming to processes for preparing Such reconstitutable formulations, ton. The Science and Practice of Pharmacy, 19th edition to therapeutic methods of use of Such formulations and to (1995), Mack Publishing, pp. 1544-1546. According to use of Such formulations in manufacture of medicaments. Remington, excipients often are added to the therapeutic agent to increase the amount of Solids, So that the resulting BACKGROUND OF THE INVENTION powder is more readily visible when the amount of the 0003) Inhibition of cyclooxygenase (COX) enzymes is therapeutic agent is very Small. "Some consider it ideal for believed to be at least the primary mechanism by which the dried-product plug to occupy essentially the same Vol nonsteroidal anti-inflammatory drugs (NSAIDs) exert their ume as that of the original Solution. To achieve this, the characteristic anti-inflammatory, antipyretic and analgesic Solids content of the original product must be between effects, through inhibition of prostaglandin Synthesis. Con approximately 5 and 25%. Among the Substances found ventional NSAIDS Such as ketorolac, diclofenac, naproxen and salts thereof inhibit both the constitutively expressed most useful for this purpose, usually as a combination, are COX-1 and the inflammation-associated or inducible Sodium or potassium phosphates, citric acid, tartaric acid, COX-2 isoforms of cyclooxygenase at therapeutic doses. gelatin and carbohydrates Such as dextrose, mannitol and Inhibition of COX-1, which produces prostaglandins that are dextran.'Remington, loc. cit. necessary for normal cell function, appears to account for certain adverse side effects that have been associated with 0008 Parecoxib, disclosed in U.S. Pat. No. 5,932,598 to use of conventional NSAIDs. By contrast, selective inhibi Talley et al., is one of a class of water-Soluble prodrugs of tion of COX-2 without Substantial inhibition of COX-1 leads selective COX-2 inhibitory drugs. Parecoxib rapidly con to anti-inflammatory, antipyretic, analgesic and other useful verts to the Substantially water-insoluble selective COX-2 therapeutic effects while minimizing or eliminating Such inhibitory drug Valdecoxib following administration to a adverse side effects. Selective COX-2 inhibitory drugs such Subject. Parecoxib also converts to Valdecoxib upon expo as celecoxib and rofecoxib, first commercially available in Sure to water, for example upon dissolution in water. The 1999, have therefore represented a major advance in the art. high water Solubility of parecoxib, particularly of Salts of These drugs are formulated in a variety of orally deliverable parecoxib Such as the Sodium Salt, by comparison with most dosage forms. selective COX-2 inhibitory drugs such as celecoxib and 0004 Parenteral routes of administration, including Sub Valdecoxib, has led to interest in developing parecoxib for cutaneous, intramuscular and intravenous injection, offer parenteral use. Parecoxib, having the structural formula (I) numerous benefits over oral delivery in particular situations, below, itself shows weak in vitro inhibitory activity against for a wide variety of drugs. For example, parenteral admin both COX-1 and COX-2, while Valdecoxib (II) has strong istration of a drug typically results in attainment of a inhibitory activity against COX-2 but is a weak inhibitor of therapeutically effective blood Serum concentration of the COX-1. drug in a shorter time than is achievable by oral adminis tration. This is especially true of intravenous injection, whereby the drug is placed directly in the bloodstream. (I) Parenteral administration also results in more predictable blood Serum concentrations of the drug, because losses in the gastrointestinal tract due to metabolism, binding to food and other causes are eliminated. For similar reasons, O M parenteral administration often permits dose reduction. / CH Parenteral administration is generally the preferred method e of drug delivery in emergency situations, and is also useful O in treating Subjects who are uncooperative, unconscious, or S. M otherwise unable or unwilling to accept oral medication. N 0005 Relatively few NSAIDs are commercially avail able in injectable form. Non-selective NSAIDs such as ketorolac tromethamine Salt that are available for parenteral US 2003/0078266 A1 Apr. 24, 2003 0013 A still further embodiment of the invention is an -continued injectable Solution prepared by reconstitution of the com (II) position. O 0014) A still further embodiment of the invention is an H.N/ article of manufacture comprising a Sealed vial having 4 CH contained there within a unit dosage amount of the compo Sition in a Sterile condition. e O S / 0015. A still further embodiment of the invention is a N method of treating or preventing a COX-2 mediated disease or disorder in a Subject, the method comprising (a) recon Stituting a unit dosage amount of the composition in a physiologically acceptable Volume of a parenterally accept able Solvent liquid to form an injectable Solution, and (b) injecting the Solution parenterally into the Subject. 0009. Other water-soluble selective COX-2 inhibitory drugs and prodrugs are known. For example, U.S. Pat. No. 0016. In all of the above embodiments, an especially 6,034,256 to Carter et al. discloses a series of water-soluble preferred therapeutic agent is a water-Soluble Salt of pare benzopyrans said to be useful as selective COX-2 inhibitory coxib. It is Surprisingly found that parecoxib, upon drugs, including the compound (S)-6,8-dichloro-2-(trifluo parenteral administration, exhibits through conversion to romethyl)-2H-1-benzopyran-3-carboxylic acid (Ell) and Valdecoxib Substantially equal anti-inflammatory and anal salts thereof. gesic effect at equal dose to Valdecoxib itself. Thus, accord ing to a yet further embodiment of the invention, there is provided a method of treating or preventing a COX-2 (III) mediated disease or disorder in a Subject, the method com prising parenterally administering parecoxib or a Salt thereof to the Subject at a parecoxib dosage
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,036,067 Girard Et Al
    United States Patent (19) 11 Patent Number: 5,036,067 Girard et al. 45 Date of Patent: Jul. 30, 1991 (54) DBENZOHETEROCYCLIC HYDROXAMIC 2191194A 6/1987 United Kingdom . ACDS AND HYDROXY UREAS AS OTHER PUBLICATIONS INHIBITORS OF 5-LPOXYGENASE P. K. Kadaba, The Synthesis of Some Phenothiazinyl (75) Inventors: Yves Girard; Pierre Hamel; Daniel Ketones and Their Derivatives, J. Het, Chen. 3, 345 Delorme, all of Quebec, Canada (1966). (73) Assignee: Merck & Co., Inc., Rahway, N.J. C. M. Suter, et al., The Directive Influences of Oxygen (21) Appl. No.: 493,527 and Sulfur, J.A.C.S. 58,717 (1936). Primary Examiner-C. Warren Ivy 22 Filed: Mar. 14, 1990 Assistant Examiner-Celia Chang (51) Int, Cl. ..................... A61K 31/54; A61K 31/55; Attorney, Agent, or Firm-Hesna J. Pfeiffer; Gabriel CO7D 279/18; CO7D 281/12 Lopez 52) U.S. C. ................................. 514/224.8; 514/21 i; 514/431; 514/434; 514/436; 540/551; 544/350; 57 ABSTRACT 544/38; 544/39; 549/10; 549/11; 549/12; 549/16; 549/17 Compounds having the formula I: (58) Field of Search .................... 540/551; 544/35, 38, 544/39; 549/10, 11, 12, 16, 17; 514/211, 224.8, R1 R3 431, 434, 436 (56) References Cited U.S. PATENT DOCUMENTS S OM 3,519,622 7/1970 Sutton ................................... 544/35 R2 3,639,612 2/1972 De Long............................... 544/35 (O) ck'l-N-y 4,536,507 8/1985 Rokach et al. ...................... 514/364 O 4,576,940 3/1986 Tahara et al. ....................... 514/212 4,666,907 5/1987 Fortin et al.
    [Show full text]
  • Chronic Pelvic Pain in Women (1 of 16)
    Chronic Pelvic Pain in Women (1 of 16) 1 Patient presents w/ symptoms suggestive of chronic pelvic pain (CPP) 2 3 COMMON EVALUATION Yes CAUSES OF CPP Do symptoms point to a • Treat according specific disease? to specifi c disease No 4 CHRONIC PELVIC PAIN SYNDROME CPPS EVALUATE & TREAT FOR SPECIFIC CONDITIONS: • Gastrointestinal Are • Gynecological symptoms organ Yes • Musculoskeletal specifi c? • Neurological • Psychological • Sexual No • Urological A MultidisciplinaryMIMS treatment CONSIDER GENERAL ANALGESIC TREATMENT OF CPP GENERAL ANALGESIC © TREATMENT OF CPP See next page B1 © MIMS 2019 Chronic Pelvic Pain in Women (2 of 16) GENERAL ANALGESIC TREATMENT OF CPP Is the pain neuropathic1 in nature? CHRONIC PELVIC PAIN CHRONIC PELVIC Yes No B Pharmacological therapy B Pharmacological therapy 1st-line trial agents: • Paracetamol • Amitriptyline or • NSAIDs • Gabapentin Alternative agents: • Nortriptyline • Pregabalin • Topical Capsaicin REFER BACK TO Is pain relief Yes PRIMARY CARE adequate? PHYSICIAN Is pain relief • CONTINUE Yes No adequate? TREATMENT • CONSIDER DOSE REDUCTION CONSIDER TRIAL No W/ NEUROPATHIC AGENTS • CONSIDER ADDING DIFFERENT 1STLINE AGENT • ROTATE AGENTS Is pain relief Yes adequate? Is pain relief Yes No adequate? MIMS No REFER TO PAIN SPECIALIST 1Please see Neuropathic© Pain disease management chart for further information. Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B2 © MIMS 2019 Chronic Pelvic Pain in Women (3 of 16) 1 CHRONIC
    [Show full text]
  • Formulations Comprising Nanoparticulate Meloxicam
    (19) TZZ¥ZZ¥__T (11) EP 3 090 731 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.11.2016 Bulletin 2016/45 A61K 9/14 (2006.01) A61K 31/5415 (2006.01) (21) Application number: 16161176.9 (22) Date of filing: 27.02.2004 (84) Designated Contracting States: • Ryde, Tuula AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Malvern, PA Pennsylvania 19355 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR • Pruitt, John, D. Suwanee, GA Georgia 30024 (US) (30) Priority: 03.03.2003 US 450705 P • Kline, Laura Harleysville, PA Pennsylvania 19438 (US) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (74) Representative: Wichmann, Hendrik 08006465.2 / 1 938 803 Wuesthoff & Wuesthoff 04785761.0 / 1 617 816 Patentanwälte PartG mbB Schweigerstraße 2 (71) Applicant: DV Technology LLC 81541 München (DE) Wilmington, Delaware 19801 (US) Remarks: (72) Inventors: This application was filed on 18-03-2016 as a • Cooper, Eugene, R. divisional application to the application mentioned Berwyn, PA Pennsylvania 19312 (US) under INID code 62. (54) FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM (57) The present invention is directed to composi- than about 2 microns; wherein said effective average par- tions comprising meloxicam. The stable meloxicam com- ticle size is different than the particle size of the nano- positions comprise (a) nanoparticulate particles of mel- particulate particles of meloxicam (a); and (c) at least one oxicam having an effective average particle size of less surface stabilizer. The invention relates also to uses of than about 2000 nm, (b) particles of meloxicam having the composition.
    [Show full text]
  • European Patent Office
    (19) *EP003643305A1* (11) EP 3 643 305 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.04.2020 Bulletin 2020/18 A61K 31/196 (2006.01) A61K 31/403 (2006.01) A61K 31/405 (2006.01) A61K 31/616 (2006.01) (2006.01) (21) Application number: 18202657.5 A61P 35/00 (22) Date of filing: 25.10.2018 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • LAEMMERMANN, Ingo GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 1170 Wien (AT) PL PT RO RS SE SI SK SM TR • GRILLARI, Johannes Designated Extension States: 2102 Bisamberg (AT) BA ME • PILS, Vera Designated Validation States: 1160 Wien (AT) KH MA MD TN • GRUBER, Florian 1050 Wien (AT) (71) Applicants: • NARZT, Marie-Sophie • Universität für Bodenkultur Wien 1140 Wien (AT) 1180 Wien (AT) • Medizinische Universität Wien (74) Representative: Loidl, Manuela Bettina et al 1090 Wien (AT) REDL Life Science Patent Attorneys Donau-City-Straße 11 1220 Wien (AT) (54) COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS (57) The invention relates to a composition compris- ing senescent cells. The invention further relates to an ing one or more inhibitors capable of inhibiting at least in vitro method of identifying senescent cells in a subject two of cyclooxygenase-1 (COX-1), cyclooxygenase-2 and to a method of identifying candidate compounds for (COX-2) and lipoxygenase for use in selectively eliminat- the selective elimination of senescent cells. EP 3 643 305 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 3 643 305 A1 2 Description al.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Inflammatory Drug
    Abbreviations used: AR(s), adverse hepatotoxicity, 17 reaction(s); ADR(s), adverse drug manufacturers, 9 reaction(s); NSAID(s), non-steroid anti­ amorfazone, trade mark names and inflammatory drug(s) manufacturers, 9 Amuno, generic name and manufacturer, 12 anaemia absorption interactions, drug, 180-1 aplastic, 83 acemetacin, trade mark names and report rate, 33 manufacturers, 8 haemolytic, 84-5 acetyl salicylic acid, see Aspirin in rheumatoid patients, inappropriate action, drug, ~ pharmacoactivity therapy, 250 activation (of drugs), 243-5, 246, 247 anaphylaxis/anaphylactoid reactions, 17, pathway, 244 81 Actol, generic name and manufacturer, 13 Anaprox, generic name and manufacturer, Actosal, generic name and manufacturer, 13 9 angioedema, 6 acyl-coenzyme A formation, 221-2 angiotensin-converting enzyme, 195, 196 adjuvant induced arthritis, ~ inhibitors arthritis function, 195 Af1oxan, generic name and manufacturer, NSAID interactions with, 195-200 14 animal(s) age see also elderly experimentation, ethics of, 267 gastrointestinal susceptibility re­ inter species differences in lated to, 164, 286-8 propionate chiral inversion, use of anti-arthritics correlated 222-3, 223 with, 152 Ansaid, generic name and manufacturer, aged, the, ~ elderly 11 agranulocytosis antacids, 292 incidence, 7, 100-2 passim effect on drug absorption, 180, 181 in Sweden, 66, 67 NSAID interactions with, 185, 193 pyrazolone-induced, 7, 99-104 anthranilic acid, relative safety, 18 analytical epidemiological anti-arthritic drugs, ~ antirheumatic studies, 101-3 drugs
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Oral Non-Steroidal Anti-Inflammatory Drugs Versus Other Oral Analgesic Agents for Acute Soft Tissue Injury (Review)
    Cochrane Database of Systematic Reviews Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury (Review) Jones P, Dalziel SR, Lamdin R, Miles-Chan JL, Frampton C Jones P, Dalziel SR, Lamdin R, Miles-Chan JL, Frampton C. Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD007789. DOI: 10.1002/14651858.CD007789.pub2. www.cochranelibrary.com Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 7 OBJECTIVES ..................................... 8 METHODS ...................................... 8 RESULTS....................................... 12 Figure1. ..................................... 13 Figure2. ..................................... 17 Figure3. ..................................... 18 Figure4. ..................................... 23 Figure5. ..................................... 24 Figure6. ..................................... 25 ADDITIONALSUMMARYOFFINDINGS . 26 DISCUSSION ..................................... 34 AUTHORS’CONCLUSIONS . 36 ACKNOWLEDGEMENTS . 37 REFERENCES ....................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub
    US 2004O156872A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0156872 A1 Bosch et al. (43) Pub. Date: Aug. 12, 2004 (54) NOVEL NMESULIDE COMPOSITIONS application No. 09/572,961, filed on May 18, 2000, now Pat. No. 6,316,029. (75) Inventors: H. William Bosch, Bryn Mawr, PA (US); Christian F. Wertz, Brookhaven, Publication Classification PA (US) (51) Int. Cl. ............................ A61K 9/14; A61K 9/00 Correspondence Address: FOLEY AND LARDNER (52) U.S. Cl. ............................................ 424/400; 424/489 SUTE 500 3000 KSTREET NW WASHINGTON, DC 20007 (US) (57) ABSTRACT (73) Assignee: Elan Pharma International Ltd. The present invention provides nanoparticulate nimeSulide (21) Appl. No.: 10/697,703 compositions. The compositions preferably comprise nime (22) Filed: Oct. 31, 2003 Sulide and at least one Surface Stabilizer adsorbed on or asSociated with the Surface of the nimeSulide particles. The Related U.S. Application Data nanoparticulate nimeSulide particles preferably have an effective average particle size of less than about 2000 nm. (63) Continuation-in-part of application No. 10/276,400, The invention also provides methods of making and using filed on Jan. 15, 2003, which is a continuation of nanoparticulate nimeSulide compositions. US 2004/O156872 A1 Aug. 12, 2004 NOVEL NMESULIDE COMPOSITIONS tion;' U.S. Pat. Nos. 5,399,363 and 5,494,683, both for “Surface Modified Anticancer Nanoparticles; U.S. Pat. No. RELATED APPLICATIONS 5,401,492 for “Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents,” 0001. This application is a continuation-in-part of U.S. U.S. Pat. No.
    [Show full text]
  • Pub. No.: US 2007/0231396 A1 Ray (43) Pub
    US 20070231396A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0231396 A1 Ray (43) Pub. Date: Oct. 4, 2007 (54) MEDICATION SPRAY FORMULATION Publication Classification (51) Int. Cl. A 6LX 36/899 (2006.01) A6IR 36/47 (2006.01) (76) Inventor: Charles D. Ray, Santa Barbara, CA A6II 3/56 (2006.01) (US) A6II 3/545 (2006.01) A 6LX 9/50 (2006.01) (52) U.S. Cl. ......................... 424/490; 424/731; 424/750; 514/200: 514/179 Correspondence Address: DICKE, BILLIG & CZAJA FIFTH STREET TOWERS (57) ABSTRACT 100 SOUTH FIFTH STREET, SUITE 2250 MINNEAPOLIS, MN 55402 (US) Formulations for delivery of a pharmaceutical agent include a thixotropic agent. The pharmaceutical agent may be slowly released from a hydrogel or microcapsule in the spray formulation. Various formulations of reasonable thixotropic (21) Appl. No.: 11/392.403 and hydrogel media are useful. Droplet size and thixotropy determine the distribution of the material along body sur faces and tissues such as the respiratory passages, and limit the displacement, running or dripping of the sprayed (22) Filed: Mar. 29, 2006 medium from its intended sites. US 2007/0231396 A1 Oct. 4, 2007 MEDCATION SPRAY FORMULATION would be welcomed by both manufacturers of health care products and consumers of Such products. FIELD OF THE INVENTION SUMMARY OF THE INVENTION 0001. The invention relates to thixotropic formulations for spray media delivery to body Surfaces and tissues such 0006 The present invention provides a thixotropic fluid as nasopharyngeal passages. The thixotropic effect allows media composition that is capable of being sprayed onto a for good fluidity during spraying but prevents running or patient's tissue (e.g., skin, wound, nasal cavity/mucous drippage loss of the medication from the body Surface so membrane), and generally consists of a primary carrier sprayed.
    [Show full text]